HONG KONG – The bacterial metabolite prodigiosin and its analogue, obatoclax, have been shown to have therapeutic activity in advanced breast cancer, providing the rationale for clinical trials, Chinese researchers reported in the Oct. 31, 2016, online edition of Proceedings of the National Academy of Sciences.